WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

REVIEW ARTICLE ON Gene Therapy Used in Cancer Treatment

[1]Tahsin Raza, [2] Md. Salman Farsi, [3] Kamalesh Mistry

[1 2] Student of B Pharma, [3] Assistant Professor
Faculty of Pharmaceutical Science, Mewar University (Rajasthan)

ABSTRACT :

Gene remedy has been an encouraging frontier within the battle towards most cancers, providing fantastically targeted and customised remedy tactics. This summary discusses the principles of gene remedy, its assorted methods in most cancers prevention, state-of-the-art clinical trials, challenges in its improvement, and future instructions. By coupling genetic engineering with oncology, gene remedy is able to flip most cancers into a terminal contamination into a attainable or possibly curable state.Gene therapy is a promising area in cancer treatment through the targeting of the disorder at the molecular level. In contrast to traditional treatment regimes that constantly attack both cancerous and healthy cells, gene therapy aims to correct or modify the genetic information responsible for cancer development.

1.Introduction

Cancer is a challenging traditional remedies such as surgery, chemotherapy, and radiation therapy have greatly evolved affected person consequences, their limitations, along with systemic toxicity and the development of drug. Gene therapy, an innovative approach that entails manipulating a affected person's genes to treat or avoid disease, has shown a promising future in the battle against cancer. This review delves into the many gene therapy packages in cancer, outlines the significant thing challenges preventing its widespread uptake, and addresses the exciting future directions that hold the potential to transform cancer treatment. Cancer remains a major cause of morbidity and mortality worldwide, with traditional treatments such as chemotherapy, radiation, and surgery often associated with significant side effects and limited long-term benefits. Gene therapy provides a unified approach with the help of targeting the disorder at the molecular level. But these approaches can be limited with the help of resistance, toxicity, and non-specificity. Gene treatment provides an one-of-a-kind healing alternative with the altering genetic material within the cancer cell or the individual's immune cells in order to put a stop towards tumor advancement.

2. Gene Remedy Principles

*** Gene Augmentation Remedy:** Inserting functional tumor suppressor genes in a majority of cancer cells which had lost its functional status. It seeks to return normal everyday cell control measures to prevent uninhibited growth.

*** Oncolytic Virotherapy:** Using genetically engineered viruses that preferentially infect and kill the majority of cancer cells while sparing healthy tissues.

*** Gene-Directed Enzyme Prodrug Therapy (GDEPT):** Later, a non-toxic prodrug is given, which is subsequently transformed into a cytotoxic drug especially in the tumor microenvironment with minimal systemic toxicity.

***Immunogene Therapy:** Activation of the patient's immune device to identify and ruin most cancers cells. It may include gene transfer encoding cytokines, co-stimulators, or antigens associated with tumors into immune cells or directly into the tumor

***Anti-angiogenic Gene Therapy:** Prevention of angiogenesis, that is, preventing the formation of new blood vessels that supply nutrients and oxygen to tumors, and thus preventing tumor growth and metastasis.This involves returning genes coding for angiogenesis inhibitors.

3.Current Landscape and Clinical Applications

Though the landscape of most cancers gene remedy is ongoing, a gigantic leap forward has been attained, with quite a number of treatments achieving clinical trials and others getting regulatory agency approval. Prime examples include:

*** Tisagenlecleucel (Kymriah) and Axicabtagene ciloleucel (Yescarta):** These CAR T-mobile therapies are legal for some hematologic malignancies such as relapsed or refractory B-cellular lymphomas, and acute lymphoblastic leukemia. They constitute genetically modifying a patient's T-cells into particular chimeric antigen receptors (CARs) that especially target most cancer cells with the CD19 marker.

*** Talimogene laherparepvec**: In addition to those established treatments, several scientific trials are examining the effectiveness of many gene therapy methods for a significant number of cancers, including stable tumors such as prostate, breast, and lung cancer. The trials are testing new gene delivery vectors, with a focus on methods, and combinations with other cancer therapies.

• Replace or disable mutated genes causing most cancers

• Deliver toxic genes specifically to cancer cells, without damaging daily cells Delivery vehicles include viral vectors (such as adenoviruses and lentiviruses) and non-viral methods (such as liposomes and nanoparticles), which transfer recovery genes into cancer tissues

Clinical Applications

Gene therapy has advanced from bench to bedside at a very fast rate over the last decade, bringing new hope to cancer patients of all types. In contrast to many standard therapies, which tend to both harm and benefit both healthy tissue and cancer cells, gene therapy is engineered to specifically target and alter genetic material in cancer cells or in associated biological systems. Its specificity maximizes therapeutic advantage with minimal side effects. Clinical uses of gene therapy for oncology represent a broad set of strategies encompassing immune system alteration, suppression of tumors, and cell-targeted destruction.

3.1. Tumor Suppressor Gene Replacement

Other cancers arise from the loss or alteration of tumor suppressor genes like TP53 that regulate cell growth. Gene therapy seeks to introduce functional versions of these genes back into cancer cells, so their function is regained to monitor cell division and initiate cell death when necessary. It introduces a normal p53 gene into cancerous head and neck tumors to improve the efficiency of radiation treatment.

3.2. Suicide Gene Therapy

In this strategy, cancer cells are genetically engineered to produce an enzyme that metabolizes a non-toxic prodrug into a toxic compound, specifically killing the tumor cells without harming normal cells. One of the most used systems is the HSV-TK (herpes simplex virus thymidine kinase) gene, which induces the antiviral drug ganciclovir. Clinical trials have investigated suicide gene therapy for the treatment of: Brain tumors (e.g., glioblastoma) Prostate cancer Pancreatic cancer .

3.3. Oncolytic Virus Therapy

Oncolytic viruses are genetically modified viruses that specifically infect and kill tumor cells while activating an immune response. They may also be made to express therapeutic genes that have an added anti-cancer effect. It's a herpes virus that is engineered to kill tumor cells and induce GM-CSF, which enhances immune activity.

3.4. Anti-Angiogenesis Gene Therapy

Gene therapy may be employed to inhibit this process (angiogenesis) by transferring genes that disrupt blood vessel formation. Although still largely in the experimental stage, anti-angiogenic gene therapies are being explored in: Colorectal cancer Ovarian cancer Glioma

3.5. Immunomodulatory Gene Therapy

This strategy augments the immune system's capacity to combat cancer by transferring genes that code for immune-stimulating cytokines such as: Interleukin-2 (IL-2) Interferon-alpha Granulocyte-macrophage colony-stimulating factor (GM-CSF) These treatments may be delivered locally to the tumor or systemically to engage immune cells. They are under investigation in several types of solid tumors such as renal cell carcinoma, melanoma, and non-small cell lung carcinoma.

4. Mechanisms of Gene Therapy in Cancer

Gene therapy in cancer may be attempted in a variety of ways:

Gene Replacement Therapy

This is replacing a defective or absent tumor suppressor gene, e.g., TP53, with a functional one to correct normal cell regulation.

Gene Silencing

Techniques such as RNA interference (RNAi) can be used to silence specific oncogenes, which will hinder the development and metastasis of cancer.

Suicide Gene Therapy

Genes that transform non-toxic prodrugs into toxins are introduced into cancer cells in this case, where they selectively kill them.

Immunomodulatory Gene Therapy

This approach strengthens the immune system against cancer through the introduction of genes that activate the immune cells, e.g., interleukins or tumor antigens.

Oncolytic Virus Therapy

Genetically altered viruses have been designed to infect and destroy cancer cells in a targeted manner, and to induce anti-tumor immunity.

5. Delivery Methods of Gene Therapy in Cancer Treatment

One of the most critical obstacles in gene therapy is delivering the genetic material into the target tumor tissues without getting destroyed or creating unwanted immune responses. There are different delivery systems that have been created, and they can broadly be divided as viral and non-viral vectors. All such systems possess positive points, shortcomings, and versatility for different categories of cancer.

5.1.Viral Vectors:

They are designed to eliminate their disease-inducing genes but retain their delivery efficiency. The most commonly utilized ones are: Adenoviruses They are also utilized frequently in cancer gene therapy since they are extremely effective in gene transfer. They have the potential to induce vigorous immune reactions and are mainly utilized for transient expression. Retroviruses and Lentiviruses Lentiviruses, which are a member of retroviruses, infect non-dividing cells and are used in more sophisticated therapies such as CAR-T cell therapy. Adeno-Associated Viruses (AAVs) AAVs are low in immunogenicity and possess a capability of providing long-term expression in cells.. They lack high genetic capacity, but they are safer in certain types of cancer gene therapy. Herpes Simplex Virus (HSV) HSV vectors are particularly useful in targeting cancer cells of the nervous system. Altered HSV is also used in oncolytic virus therapies that selectively target tumor cells and destroy them.

5.2. Non-Viral Vectors:

Non-viral delivery tends to be safer compared to viral vectors, lower immune response risk and easier to produce. But they are more likely to experience difficulty in delivery efficiency. Liposomes and Lipid Nanoparticles These are small, spherical vesicles that are capable of transporting DNA or RNA and can fuse with the cell membrane to release their content. Lipid-based delivery carriers occur in several approved treatments like mRNA vaccines and research gene therapies for cancer. Polymeric Nanoparticles Polymers like polyethyleneimine (PEI) and PLGA (poly lactic-co-glycolic acid) are employed to form complexes with DNA or RNA that provide stability and enhanced cellular uptake. Physical Methods Techniques like electroporation, gene gun, and ultrasound can physically inject DNA into cells. They are mostly used in experimental or in situ applications due to their invasiveness Inorganic Nanoparticles Gold nanoparticles, silica systems, and magnetic particles are being studied for targeted delivery of genes. They offer features like controlled release and the potential to track inside the body.

5.3. Targeted Delivery Methods:

For enhanced specificity, current gene therapy studies aim to work with targeted delivery systems. These employ ligands, antibodies, or other molecules that target cancer-specific antigens to deliver the gene therapy vectors to the tumor cells themselves.

Conclusion

Gene therapy, by addressing the genetic root of malignancy, promises more curative and less toxic treatments. Although there are still obstacles to overcome, scientific progress and clinical developments continue to pave the way for gene therapy to become a cornerstone of modern oncology. Gene therapy is an uplifting and state-of-the-art approach in cancer cure and prevention that battles the sickness in its fundamental genes instead of attempting to rid itself of signs and symptoms. As it is capable of curing, replacing, or silencing rogue genes, the method carries a lot of hope with exceedingly exact and patient-specific cancer therapy coupled with diminished side effects in contrast to other current practices. From gene-altered viruses that target and destroy cancer cells to genetically modified immune cells programmed to seek and destroy cancer, gene therapy is already proving successful in the test tubes and clinical trials.

REFERENCES :

1. American Cancer Society. (2023). Gene Therapy for Cancer Treatment.
2. National Cancer Institute. (2024). Targeted Cancer Therapies.
3. Abedi MR, Wixon Jo, and Edelstein ML. An update on global gene remedy scientific trials through 2007.
4. Johann DJ Jr, Mbeunkui F. A critical interaction between cancer and the tumor microenvironment is evaluated. Pharmacol. Cancer Chemother 2009; 63:571-582.
5. Rojas-Martínez A, Hernández-García A, Aguilar-Córdova E, Barrera-Saldaña HA, and Martínez-Dávila IA. This is a genetic cure for most malignancies. 54(1):57-67 in Rev Invest Clin. 2002.
6. A collection of medical gene cure trials' losing statistics. 2009; 9:910-921; J Gene Med. 98. Peng Z. The use of recombinant human Adp53 as a medicinal agent to treat cancer is currently quite popular in China.
7. American Cancer Society. (2023). Gene therapy and cancer. Retrieved from https://www.cancer.org. Provides a general overview of how gene therapy is used in cancer, including types and mechanisms.
8. National Cancer Institute. (2023). CAR T-cell therapy: What to expect. Retrieved from https://www.cancer.govDiscusses the development and clinical application of CAR-T cell therapy in cancer treatment.
9. Rosenberg, S. A., & Restifo, N. P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348(6230), 62–68.A foundational study on adoptive T-cell therapy and its role in cancer immunotherapy.

10. Pearson, S., Jia, H., Kandachi, K. (2004). China approves first gene therapy. Nature Biotechnology, 22, 3–4. Details on the approval and clinical impact of Gendicine, the first gene therapy drug approved for cancer.
11. Filley, A. C., Dey, M. (2017). Dendritic cell-based vaccination strategies for glioma. Immunotherapy, 9(12), 1073–1086.Explores immunomodulatory gene therapy and its role in treating brain tumors.
12. Mavroudi, I., & Papadaki, H. A. (2016). Gene therapy for hematologic malignancies: Recent advances and future prospects. Journal of Hematology & Oncology, 9(1), 1–13.